miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC

Zhao,Henan; Ding,Yanfang; Tie,Bi; Sun,Zhen-Feng; Jiang,Ji-Yong; Zhao,Jinyao; Lin,Xingchi; Cui,Shiying

doi:10.3892/ijo.2013.1988

miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC

Authors:
- Henan Zhao
- Yanfang Ding
- Bi Tie
- Zhen-Feng Sun
- Ji-Yong Jiang
- Jinyao Zhao
- Xingchi Lin
- Shiying Cui
View Affiliations

Affiliations: Dalian Medical University, Dalian, P.R. China, Obstetrics and Gynecology Hospital, Dalian, P.R. China
Published online on: June 20, 2013 https://doi.org/10.3892/ijo.2013.1988
Pages: 839-849

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The long-term survival for elderly patients with advanced ovarian papillary serous carcinoma (OPSC) does not exceed 30%, and the incidence and prognosis rise continuously after menopause. The aim of this study was to identify the differences in key miRNAs and their potential regulators through miRNA microarray analysis, functional target prediction, and clinical outcome between the elderly patients with advanced OPSC and ovarian clear cell carcinoma (OCC) who all suffered poor prognosis, to identify the pathogenetic basis, and to improve the understanding of the molecular basis of advanced OPCS in elderly patients. Through microarray analysis, we found 52 unique miRNAs with significant fold‑change in expression levels, of which 9 were upregulated, whereas 43 were downregulated in OCC patients compared to elderly OPSC patients with advanced stage. Among these prediction miRNAs, miR-30a*, miR-30e* and miR-505* were found to have some common cancer-related targets. Lower expression of these three miRNAs of advanced OPSC in elderly patients, all associated with significantly poorer survival rate, strongly suggesting that they could be critical oncogenes and take important roles in OPSC etiology in elderly patients with advantaged stage. Functional analyses support the above hypothesis. Their targets, ATF3, STMN1 and MYC suggest that OPSC also has aggressive biological behavior when presented with advanced stage, and support the epidemiology results that incidence and mortality of advanced OPSC increases continuously. miR-30a*, miR-30e* and miR-505* may be important pathogenetic factors for OPSC in elderly patients with advanced stage. Age could be regarded as a continuous covariate in this process. This may improve the understanding of molecular underpinnings of advanced OPSC in elderly patients, and provide improved diagnostic, prognostic and therapeutic approaches.

View Figures

View References

1	Pignata S and Vermorken JB: Ovarian cancer in the elderly. Crit Rev Oncol Hematol. 49:77–86. 2004. View Article : Google Scholar
2	Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 113:249–255. 2009. View Article : Google Scholar : PubMed/NCBI
3	Liu JF, Hirsch MS, Lee H and Matulonis UA: Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 115:401–406. 2009. View Article : Google Scholar : PubMed/NCBI
4	Moore DH, Kauderer JT, Bell J, Curtin JP and Van Le L: An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol. 94:368–374. 2004. View Article : Google Scholar
5	Shih KK, Qin LX, Tanner EJ, et al: A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol. 121:444–450. 2011. View Article : Google Scholar : PubMed/NCBI
6	Yancik R, Ries LG and Yates JW: Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. Am J Obstet Gynecol. 154:639–647. 1986. View Article : Google Scholar : PubMed/NCBI
7	Chan JK, Teoh D, Hu JM, Shin JY, Osann K and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
8	Wyman SK, Parkin RK, Mitchell PS, et al: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 4:e53112009. View Article : Google Scholar : PubMed/NCBI
9	Van Jaarsveld MT, Helleman J, Berns EM and Wiemer EA: MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 42:1282–1290. 2010.PubMed/NCBI
10	Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
11	Yoshida S, Furukawa N, Haruta S, et al: Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev. 35:608–615. 2009. View Article : Google Scholar : PubMed/NCBI
12	Pectasides D, Pectasides E, Psyrri A and Economopoulos T: Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist. 11:1089–1094. 2006. View Article : Google Scholar : PubMed/NCBI
13	Snowdon J, Zhang X, Childs T, Tron VA and Feilotter H: The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One. 6:e228282011. View Article : Google Scholar : PubMed/NCBI
14	Cui S, Li C, Ema M, Weinstein J and Quaggin SE: Rapid isolation of glomeruli coupled with gene expression profiling identifies downstream targets in Pod1 knockout mice. J Am Soc Nephrol. 16:3247–3255. 2005. View Article : Google Scholar : PubMed/NCBI
15	American Cancer Society. Global Cancer Facts and Figures 2007. American Cancer Society Inc; Atlanta, GA: 2007
16	Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ and Cronin KA: SEER Cancer Statistics Review: 1975–2008. National Institutes of Health; Bethesda, MD: 2011
17	Kim MS, In SG, Park OJ, et al: Increased expression of activating transcription factor 3 is related to the biologic behavior of cutaneous squamous cell carcinomas. Hum Pathol. 42:954–959. 2011. View Article : Google Scholar : PubMed/NCBI
18	Li ZD, Hu XW, Wang YT and Fang J: Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1. FEBS Lett. 583:1999–2003. 2009. View Article : Google Scholar : PubMed/NCBI
19	Hai T and Hartman MG: The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene. 273:1–11. 2001. View Article : Google Scholar
20	Thompson MR, Xu D and Williams BR: ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl). 87:1053–1060. 2009. View Article : Google Scholar : PubMed/NCBI
21	Pelzer AE, Bektic J, Haag P, et al: The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol. 175:1517–1522. 2006. View Article : Google Scholar : PubMed/NCBI
22	Janz M, Hummel M, Truss M, et al: Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood. 107:2536–2539. 2006. View Article : Google Scholar
23	Bandyopadhyay S, Wang Y, Zhan R, et al: The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res. 66:11983–11990. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ishiguro T, Nagawa H, Naito M and Tsuruo T: Inhibitory effect of ATF3 antisense oligonucleotide on ectopic growth of HT29 human colon cancer cells. Jpn J Cancer Res. 91:833–836. 2000. View Article : Google Scholar : PubMed/NCBI
25	Hsieh SY, Huang SF, Yu MC, et al: Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog. 49:476–487. 2010.PubMed/NCBI
26	Lee HS, Lee DC, Park MH, et al: STMN2 is a novel target of beta-catenin/TCF-mediated transcription in human hepatoma cells. Biochem Biophys Res Commun. 345:1059–1067. 2006. View Article : Google Scholar : PubMed/NCBI
27	Su D, Smith SM, Preti M, et al: Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer. 115:2453–2463. 2009. View Article : Google Scholar : PubMed/NCBI
28	Ponzielli R, Katz S, Barsyte-Lovejoy D and Penn LZ: Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer. 41:2485–2501. 2005. View Article : Google Scholar : PubMed/NCBI
29	Lee YY, Kim TJ, Kim MJ, et al: Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol. 122:541–547. 2011. View Article : Google Scholar : PubMed/NCBI